Fred Hutchinson Cancer Center
Who we are
Fred Hutchinson Cancer Center is an independent, nonprofit, unified adult cancer care and research center that is clinically integrated with UW Medicine, a world leader in clinical care, research and learning.
Fred Hutchinson Cancer Center was created in April 2022 by the merger of longtime partners, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance. Together, our fully integrated research and clinical care teams seek to discover new cures for the world’s deadliest diseases and make life beyond cancer a reality.
The first National Cancer Institute-designated cancer center in the Pacific Northwest, Fred Hutch is a global leader in bone marrow transplantation, HIV/AIDS, immunotherapy and COVID-19, confirming our reputation as one of the world’s leading cancer, infectious disease and biomedical research centers. Based in Seattle, Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and has network affiliations with hospitals in four states.
Fred Hutch providers include specialists in Anesthesiology, Dermatology, Endocrinology, Gastroenterology, Genetics, Gynecologic Oncology, Gynecology, Hematology, Hematology Oncology, Medical Oncology, Infectious Disease, Palliative Care, Nephrology, Pain Medicine, Pathology, Pulmonology, Psychiatry and Psychology, Radiation Oncology and Radiology, Reproductive Endocrinology and Infertility, Surgery and Urology. Fred Hutch uses the latest in molecular testing and diagnostics to treat every patient with an individualized care plan.
Fred Hutch was one of the first cancer centers in the nation to offer all three FDA-approved CAR T-cell therapies. These therapies are available to treat people living with certain types of blood cancers, including non-Hodgkin lymphoma.
Fred Hutch’s breakthrough discoveries began with Dr. E. Donnall Thomas’ groundbreaking work in bone marrow transplantation, which has boosted survival rates for certain blood cancers from nearly zero to 90%. Thomas’ work earned a Nobel Prize in 1990 and led to a potentially lifesaving option used to treat more than 1.3 million people worldwide.
Fred Hutch researchers were among the first to show the potential of the immune system to wipe out cancers. They continue to perfect this approach through a world-leading immunotherapy program, which includes a first-of-its-kind facility dedicated to providing innovative immunotherapies for cancer patients.